FindTrial
Sign In

Comparison of uterine blood flow, following two types of progesterone in recurrent miscarriage

Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/02/003406
Enrollment
101
Registered
2013-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with history of three or more miscarriages

Interventions

Intervention1: Dydrogesterone: 10mg twice daily - orally, upto 14 weeks of gestation Intervention2: Micronised Progesterone: 100mg thrice daily - vaginally, upto 14 weeks of gestation

Sponsors

Institute of Reproductive Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with three or more consecutive miscarriages up to 12 weeks of gestation followed by spontaneous conception, no apparent cause of recurrent pregnancy loss

Exclusion criteria

Exclusion criteria: Diabetes Mellitus, Luteal Phase Defect, Hypothyroidism, Hyperprolactinemia, Hyperhomocysteinemia, Uterine Defects

Design outcomes

Primary

MeasureTime frame
Ongoing Pregnancy/Live Birth Endometrial Blood FlowTimepoint: 9 months—

Secondary

MeasureTime frame
Miscarriage RateTimepoint: 24 weeks—

Countries

India

Contacts

Public ContactDr Baidyanath Chakravarty

Institute of Reproductive Medicine

bncirm@yahoo.com03323215125

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026